JP2009501777A5 - - Google Patents

Download PDF

Info

Publication number
JP2009501777A5
JP2009501777A5 JP2008522096A JP2008522096A JP2009501777A5 JP 2009501777 A5 JP2009501777 A5 JP 2009501777A5 JP 2008522096 A JP2008522096 A JP 2008522096A JP 2008522096 A JP2008522096 A JP 2008522096A JP 2009501777 A5 JP2009501777 A5 JP 2009501777A5
Authority
JP
Japan
Prior art keywords
mixture
optionally
mixtures
alcohol
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008522096A
Other languages
English (en)
Japanese (ja)
Other versions
JP5199084B2 (ja
JP2009501777A (ja
Filing date
Publication date
Priority claimed from EP05291542A external-priority patent/EP1745775B1/en
Application filed filed Critical
Publication of JP2009501777A publication Critical patent/JP2009501777A/ja
Publication of JP2009501777A5 publication Critical patent/JP2009501777A5/ja
Application granted granted Critical
Publication of JP5199084B2 publication Critical patent/JP5199084B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008522096A 2005-07-19 2006-07-19 胃保持型製剤およびそれらの製造方法 Expired - Fee Related JP5199084B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05291542A EP1745775B1 (en) 2005-07-19 2005-07-19 Gastroretentive formulations and manufacturing process thereof.
EP05291542.8 2005-07-19
PCT/IB2006/002636 WO2007010400A2 (en) 2005-07-19 2006-07-19 Gastroretentive formulations and manufacturing process thereof

Publications (3)

Publication Number Publication Date
JP2009501777A JP2009501777A (ja) 2009-01-22
JP2009501777A5 true JP2009501777A5 (enExample) 2011-03-31
JP5199084B2 JP5199084B2 (ja) 2013-05-15

Family

ID=35517256

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008522096A Expired - Fee Related JP5199084B2 (ja) 2005-07-19 2006-07-19 胃保持型製剤およびそれらの製造方法

Country Status (12)

Country Link
US (1) US9629800B2 (enExample)
EP (2) EP1745775B1 (enExample)
JP (1) JP5199084B2 (enExample)
KR (1) KR101367814B1 (enExample)
CN (1) CN101237858B (enExample)
AT (1) ATE396710T1 (enExample)
AU (1) AU2006271314B2 (enExample)
BR (1) BRPI0612901B8 (enExample)
CA (1) CA2616081C (enExample)
DE (1) DE602005007205D1 (enExample)
RU (1) RU2376983C2 (enExample)
WO (1) WO2007010400A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080076382A (ko) * 2007-02-15 2008-08-20 (주)아모레퍼시픽 실로스타졸의 제어방출 제제 및 그 제조방법
CA2738114A1 (en) 2008-09-22 2010-04-08 Rubicon Research Private Limited Compositions exhibiting delayed transit through the gastrointestinal tract
FR2945947B1 (fr) 2009-05-29 2011-07-29 Flamel Tech Sa Compositions pharmaceutiques flottantes a liberation controlee
JP5594484B2 (ja) 2009-07-06 2014-09-24 杏林製薬株式会社 中空構造を有する錠剤
EP2361615A1 (en) 2010-02-19 2011-08-31 Alfred E. Tiefenbacher GmbH & Co. KG Dipyridamole prolonged-release tablet
EP2544666A2 (en) 2010-03-09 2013-01-16 Council of Scientific and Industrial Research Gastroretentive, extended release composition of therapeutic agent
EP2561892B1 (en) * 2010-03-31 2015-05-06 Mochida Pharmaceutical Co., Ltd. Easily dosable solid preparation
CN101919817B (zh) * 2010-07-23 2012-05-30 山东齐都药业有限公司 一种拉呋替丁胃内滞留控制释放组合物
WO2013046453A1 (ja) 2011-09-30 2013-04-04 持田製薬株式会社 易服用性固形製剤
DE102012102414A1 (de) 2012-03-21 2013-10-10 Michael Dittgen Pharmazeutische Zusammensetzung für die einmal tägliche Anwendung antidiabetischer Arzneimittel wie Metformin mit Zwei-Puls-Freisetzung
WO2013168179A2 (en) * 2012-04-03 2013-11-14 Rubicon Research Private Limited Controlled release pharmaceutical formulations of antiviral agents
CN103110601B (zh) * 2013-02-04 2014-10-29 成都恒瑞制药有限公司 一种格列齐特胃漂浮片及其制备方法
FR3014692B1 (fr) * 2013-12-18 2016-01-29 Ethypharm Sa Compositions pharmaceutiques orales a retention gastrique.
TWI732337B (zh) * 2014-06-20 2021-07-01 美商梅琳塔有限責任公司 醫藥組成物及其用途
AU2017235631B2 (en) 2016-03-17 2023-03-02 Thiogenesis Therapeutics, Inc. Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders
CN107184560B (zh) * 2017-06-03 2021-02-02 寿光富康制药有限公司 二甲双胍胃滞留片及制备方法
CA3076392A1 (en) 2017-09-20 2019-03-28 Thiogenesis Therapeutics, Inc. Methods for the treatment of cysteamine sensitive disorders
WO2019126215A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
US11337920B2 (en) 2017-12-18 2022-05-24 Tris Pharma, Inc. Pharmaceutical composition comprising GHB gastro-retentive raft forming systems having trigger pulse drug release
WO2019126218A1 (en) * 2017-12-18 2019-06-27 Tris Pharma, Inc. Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release
CN109602714B (zh) * 2018-12-29 2020-06-12 广东中润药物研发有限公司 一种利伐沙班胃滞留片及其制备方法
GB2599950A (en) * 2020-10-16 2022-04-20 Zentiva Ks Pharmaceutical compositions with low amounts of nitrosamine impurities and methods for producing the same
CA3204777A1 (en) * 2021-01-13 2022-07-21 Vinay Muley A gastroretentive drug delivery system

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61148115A (ja) * 1984-12-21 1986-07-05 Tooa Eiyoo Kk 難溶性薬物の徐放性製剤及びその製造法
GB8618847D0 (en) * 1986-08-01 1986-09-10 Smith Kline French Lab Pharmaceutical formulations
FR2653337B1 (fr) * 1989-10-23 1992-02-07 Dow Corning Sa Element a liberation prolongee et procede pour le fabriquer.
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
US6120803A (en) * 1997-08-11 2000-09-19 Alza Corporation Prolonged release active agent dosage form adapted for gastric retention
IN186245B (enExample) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
AP1224A (en) 1998-03-19 2003-11-14 Bristol Myers Squibb Co Biphasic controlled release delivery system for high solubility pharmaceuticals and method.
ATE245414T1 (de) * 1998-09-14 2003-08-15 Ranbaxy Lab Ltd Oral verabreichtes system zur zeitlich und räumlich gesteuerten arzneistoffabgabe
ATE306250T1 (de) * 1998-12-23 2005-10-15 Alza Corp Dosierungsformen, die poröse partikel enthalten
US6635281B2 (en) * 1998-12-23 2003-10-21 Alza Corporation Gastric retaining oral liquid dosage form
US6797283B1 (en) 1998-12-23 2004-09-28 Alza Corporation Gastric retention dosage form having multiple layers
EA200200914A1 (ru) * 2000-03-03 2003-02-27 Рэнбакси Лабораториз Лимитед Система контроля дозирования для однократного ежедневного приема назначенного ципрофлоксацина
AU2002355686B2 (en) * 2001-07-04 2007-11-29 Sun Pharmaceutical Industries Limited Gastric retention controlled drug delivery system
AU2002302890A1 (en) * 2002-02-04 2003-12-02 Ranbaxy Laboratories Limited Hydrodynamically balancing oral drug delivery system with biphasic release
GB0205253D0 (en) * 2002-03-06 2002-04-17 Univ Gent Immediate release pharmaceutical granule compositions and a continuous process for making them
WO2003101431A1 (en) 2002-06-04 2003-12-11 J.B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical composition for controlled drug delivery system
WO2005060942A1 (en) * 2003-12-19 2005-07-07 Aurobindo Pharma Ltd Extended release pharmaceutical composition of metformin

Similar Documents

Publication Publication Date Title
JP2009501777A5 (enExample)
WO2006100281A3 (en) Solubilized ibuprofen
ES2522567T3 (es) Composición farmacéutica que comprende amlodipino y losartán
JP2009510068A5 (enExample)
JP2007302683A5 (enExample)
MX2010004292A (es) Producto de dispersion solida que contiene un compuesto a base de n-aril urea.
JP2006077018A5 (enExample)
NO20091501L (no) Farmasoytiske sammensetninger
ES2768349T3 (es) Preparación farmacéutica que comprende un derivado de fenilalanina
TW200503786A (en) Fast dissolving orally consumable films containing a modified starch for improved heat and moisture resistance
RU2010101797A (ru) Фармацевтический твердый препарат, содержащий бензазепины и способ его получения
RU2008106220A (ru) Гастроретентивные композиции и способ их изготовления
BRPI0918530B1 (pt) Granulado, seu uso e seu processo de produção, e composição.
WO2015115453A1 (ja) 口腔内速崩壊性固形製剤用組成物
ATE329581T1 (de) Pharmazeutische formulierung, die n-((1-n-butyl-4-piperidinyl)menthyl)-3,4-dihydr -2h-(1, 3)oxazino(3,2-a)indol-10-carboxamid oder ein entsprechendes salz hiervon enthält, sowie deren herstellungsprozess, welcher trockengranulierung beinhaltet
BRPI0717914A2 (pt) "metodo de formação de um comprimido"
CN102176902B (zh) 有机溶剂在莫西沙星湿法造粒中的应用
WO2008100240A3 (en) Pharmaceutical composition with sodium lauryl sulfate as an extra-granular absorption/compression enhancer and the process to make the same
WO2013119607A2 (en) Modified release formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione
EA200901191A1 (ru) Фармацевтическая композиция, содержащая активный ингредиент аторвастатин
JP2011012018A (ja) 崩壊遅延が抑制されたパロキセチン塩酸塩水和物の経口投与用医薬組成物
WO2006101794A3 (en) Stable tablet dosage forms of proton pump inhibitors
WO2005082329B1 (en) Process for the preparation of solid dosage forms of valsartan and hydrochlorthiazide
WO2007016128A3 (en) Magnesium salt proton pump inhibitor dosage forms
TW200738286A (en) Solubilized ibuprofen